Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo
Keywords: Arsenic trioxide; Cisplatin; Combination therapy; Bcr-Abl-positive leukemia; Apoptosis; APL; acute promyelocytic leukemia; ATO; arsenic trioxide; Ato-C; ATO/CDDP; CDDP; Cisplatin; CI; combination index; DRI; dose-reduction index; CML; Chronic myelogenous